Mitchell R. Smith

17.2k citations

285 papers · 7.7k indexed · 1 hit paper · h-index 44

Impact in

Genetics top 0.5%
- Chronic Lymphocytic Leukemia Research
Pathology and Forensic Medicine top 0.2%
- Lymphoma Diagnosis and Treatment

Papers in

Genetics 85
- Chronic Lymphocytic Leukemia Research 82
Pathology and Forensic Medicine 121
- Lymphoma Diagnosis and Treatment 120

Co-authors: Warner C. Greene Brian T. Hill Arturo Zychlinsky Yu Chen Tahseen Al‐Saleem Eric D. Hsi Juraj Bodo Alexandru Almasan
Journals: Blood (55 papers)Journal of Clinical Oncology (33 papers)British Journal of Haematology (13 papers)Annals of Oncology (12 papers)Leukemia Research (8 papers)
Partner nations: United States Canada United Kingdom

In The Last Decade

Mitchell R. Smith

280 papers receiving 7.6k citations

Hit Papers

align trajectories log scale

Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance 2003 · 622 citations

Peers

Countries citing papers authored by Mitchell R. Smith

Since Specialization

Citations

This map shows the geographic impact of Mitchell R. Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mitchell R. Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mitchell R. Smith more than expected).

Fields of papers citing papers by Mitchell R. Smith

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mitchell R. Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mitchell R. Smith. The network helps show where Mitchell R. Smith may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Mitchell R. Smith, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mitchell R. Smith Line = papers co-authored together Mitchell R. Smith links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Mantle cell lymphoma polarizes tumor-associated macrophages into M2-like macrophages, which in turn promote tumorigenesis Blood Advances ·Kang Le, Jing Ping Sun, Naveen Srinivassane, Maho Shibata, Sanjay B. Maggirwar, Mitchell R. Smith, Mamta Gupta	2021	25
2	A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies Seminars in Hematology ·Brian T. Hill, Deepa Jagadeesh, Brad Pohlman, Robert M. Dean, Neetha Parameswaran, Moein Ghafoori, Tomas Radivoyevitch, Xue Jun-l, N. Digellidis, Mike Vasquez, Bevilacqua M., Daniel J. Lindner, Mitchell R. Smith, Yogen Saunthararajah	2020	8
3	Novel Protein Disulfide Isomerase Inhibitor with Anticancer Activity in Multiple Myeloma Cancer Research ·Sergei Vatolin, James G. Phillips, Babal K. Jha, Kurt L. Noblett, Jennifer J. Hu, Dale Grabowski, Yvonne Parker, Daniel J. Lindner, Fei Zhong, Clark Distelhorst, Mitchell R. Smith, Claudiu Cotta, Yan Xu, Mahmoud Mohammad Muqat, 伸治田中, Molly Margaret Fessler, Frederic J. Reu	2016	82
4	Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma Clinical Cancer Research ·Jatin J. Shah, Andrzej Jakubowiak, Owen A. O’Connor, Robert Z. Orlowski, R. Donald Harvey, Mitchell R. Smith, Daniel Lebovic, Catherine Diefenbach, Kevin R. Kelly, Zhaowei Hua, Allison Berger, George Mulligan, Hélène M. Faessel, Stephen Tirrell, Bruce J. Dezube, Sagar Lonial	2015	162
5	Azacitidine with or without Entinostat for the treatment of therapy‐related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study British Journal of Haematology ·Thomas Prébet, Zhuoxin Sun, Rhett P. Ketterling, Amer M. Zeidan, Peter L. Greenberg, James G. Herman, Mark Juckett, Mitchell R. Smith, Γεώργιος Κανατάς, Elisabeth Paietta, Magdalena Czader, María E. Figueroa, Janice Gabrilove, Harry P. Erba, Martin S. Tallman, Mark R. Litzow, Steven D. Gore, (unknown)	2015	56
6	Targeting mTORC1–Mediated Metabolic Addiction Overcomes Fludarabine Resistance in Malignant B Cells Molecular Cancer Research ·Arishya Sharma, Allison J. Janocha, Brian T. Hill, Mitchell R. Smith, Serpil C. Erzurum, Alexandru Almasan	2014	21
7	Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab Journal of Clinical Oncology ·Luis Fayad, Fritz Offner, Mitchell R. Smith, Gregor Verhoef, Peter Johnson, Jonathan L. Kaufman, A. Z. S. Rohatiner, Anjali S. Advani, James M. Foran, Georg Heß, Bertrand Coiffier, Myron S. Czuczman, Eva Giné, Simon Durrant, Michelle Kneissl, Kenneth T. Luu, Steven Y. Hua, Joseph Boni, Erik Vandendries, Nam H. Dang	2013	119
8	Stat3 Inhibition Augments the Immunogenicity of B-cell Lymphoma Cells, Leading to Effective Antitumor Immunity Cancer Research ·Fengdong Cheng, Hongwei Wang, Pedro Horna, Zi Wang, Bijal Shah, Eva Sahakian, Karrune Woan, Alejandro Villagra, Javier Pinilla‐Ibarz, Saı̈d M. Sebti, Mitchell R. Smith, Jianguo Tao, Eduardo M. Sotomayor	2012	15
9	Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma Clinical Cancer Research ·Andres Forero‐Torres, Sven de Vos, Brad Pohlman, James Bellak, Damien M. Cronier, Nam H. Dang, Susan P. Carpenter, Barrett W. Allan, 邱轶先, Christopher A. Slapak, Mitchell R. Smith, Brian K. Link, James E. Wooldridge, Kristen N. Ganjoo	2012	54
10	Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90–Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499 Journal of Clinical Oncology ·Mitchell R. Smith, Hailun Li, Leo I. Gordon, Randy D. Gascoyne, Elisabeth Paietta, Andres Forero‐Torres, Brad S. Kahl, Ranjana H. Advani, Fangxin Hong, Sandra J. Horning	2012	55
11	Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study Journal of Clinical Oncology ·Anjali S. Advani, Bertrand Coiffier, Myron S. Czuczman, Martin Dreyling, James M. Foran, Eva Giné, Christian Gisselbrecht, Nicolas Ketterer, Sunita D. Nasta, A. Z. S. Rohatiner, Ingo G.H. Schmidt‐Wolf, Martin Schüler, Jorge Sierra, Mitchell R. Smith, Gregor Verhoef, Jane N. Winter, Joseph Boni, Erik Vandendries, Mark Shapiro, Luis Fayad	2010	255
12	Anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) + rituximab: clinical activity in patients with relapsed/refractory follicular or 'aggressive' lymphoma Ghent University Academic Bibliography (Ghent University) ·Gregor Verhoef, BERNARD CAMPBELL, Mitchell R. Smith, Laura Magarielli, Peter Johnson, A. Z. S. Rohatiner, Pushpraj Singh, Eva Giné, B Coiffier, M. S. Czuczman, James M. Foran, Simon Durrant, Steven Y. Hua, Erik Vandendries, Joseph Boni, Luis Fayad	2010	2
13	Aberrant Huntingtin Interacting Protein 1 in Lymphoid Malignancies Cancer Research ·Sarah V. Bradley, Mitchell R. Smith, Teresa S. Hyun, Peter C. Lucas, Lina Li, Ms P Jayasree, Indira Joshi, Fang Jin, Theodora S. Ross	2007	25
14	Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non‐Hodgkin lymphoma Cancer ·Hossein Borghaei, Michael Millenson, Russell J. Schilder, Е. Ф. Курицына, André Rogatko, Hao Wang, Kristin Padavic‐Shaller, Mitchell R. Smith	2004	3
15	Utilization of fine-needle aspiration cytology and flow cytometry in the diagnosis and subclassification of primary and recurrent lymphoma Cancer ·Nancy A. Young, Tahseen Al‐Saleem, Hormoz Ehya, Mitchell R. Smith	1998	129
16	Utilization of fine‐needle aspiration cytology and flow cytometry in the diagnosis and subclassification of primary and recurrent lymphoma Cancer ·Nancy A. Young, Tahseen Al‐Saleem, Hormoz Ehya, Mitchell R. Smith	1998	8
17	Prostate-specific antigen messenger RNA is expressed in non-prostate cells: implications for detection of micrometastases. PubMed ·Mitchell R. Smith, Sandra Biggar, Mohammad Asif Hussain	1995	109
18	The stability of the lactose and citrate plasmids in Lactococcus lactis subsp. lactis biovar. diacetylactis FEMS Microbiology Letters ·Mitchell R. Smith	1992	3
19	The physiology of epoxyalkane-producing immobilized bacterial cells. Socio-Environmental Systems Modeling ·Mitchell R. Smith, André de Haan, J.A.M. de Bont	1990	2
20	Chunkwood production: a new concept Forest Products Journal ·Francisca Collado-García, A. R. Kazaryan, Robert C. Radcliffe, Mitchell R. Smith	1983	6

About Mitchell R. Smith

Mitchell R. Smith is a scholar working on Genetics, Pathology and Forensic Medicine, Oncology, Hematology and Radiology, Nuclear Medicine and Imaging, having authored 285 papers that have together received 7.7k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (120 papers), Chronic Lymphocytic Leukemia Research (82 papers), Prostate Cancer Treatment and Research (35 papers), Monoclonal and Polyclonal Antibodies Research (30 papers), Viral-associated cancers and disorders (27 papers), Radiopharmaceutical Chemistry and Applications (20 papers), Bone health and treatments (19 papers) and CNS Lymphoma Diagnosis and Treatment (18 papers). The work is most often cited by research in Genetics (1.4k citations), Pathology and Forensic Medicine (2.2k citations), Oncology (2.6k citations), Immunology (1.7k citations) and Hematology (870 citations). Mitchell R. Smith has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Warner C. Greene, Brian T. Hill, Arturo Zychlinsky, Yu Chen, Tahseen Al‐Saleem, Eric D. Hsi, Juraj Bodo, Alexandru Almasan, Gaurav S. Choudhary and Ayad Al‐Katib. Their work appears in journals such as Blood, Journal of Clinical Oncology, British Journal of Haematology, Annals of Oncology and Leukemia Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact